---
schema_version: "secwatch.filing_event.v1"
accession: "0001437749-26-025302"
form_type: "8-K"
ticker: "GNPX"
cik: "0001595248"
company_name: "Genprex, Inc."
filed_at: "2026-08-03T11:02:13+00:00"
generated_at: "2026-08-03T11:05:21.935883+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Genprex collaborates with Roche Diagnostics to validate TROP2/PTEN biomarkers for NSCLC

## Summary
- Collaboration with Roche Diagnostics to validate TROP2 and PTEN biomarkers for patient selection in NSCLC clinical trials.
- Roche's AI-driven companion diagnostic received FDA Breakthrough Device Designation; Genprex will use same TROP2 antibody.
- Validation studies expected to complete by end of 2026, with subsequent integration into NSCLC clinical program.
- Preclinical data: high TROP2 H-scores and low PTEN H-scores predicted response; clinical data correlated with longer PFS.
- Goal to shorten patient identification and recruitment for NSCLC trials, enabling more personalized treatment.

## SEC filing metadata
- accession: 0001437749-26-025302
- form_type: 8-K
- ticker: GNPX
- cik: 0001595248
- company_name: Genprex, Inc.
- filed_at: 2026-08-03T11:02:13+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1595248/000143774926025302/0001437749-26-025302-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1595248/000143774926025302/gnpx20260802_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001437749-26-025302
- JSON: https://secwatch.observer/filing/0001437749-26-025302.json
- Plain text: https://secwatch.observer/filing/0001437749-26-025302.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.